Status of Drug Resistant TB and efforts for its control in the … · STATUS OF DRUG RESISTANT TB...
Transcript of Status of Drug Resistant TB and efforts for its control in the … · STATUS OF DRUG RESISTANT TB...
STATUS OF DRUG RESISTANT TB IN THE AFRICAN REGION: BURDEN,
CONTROL EFFORTS, CHALLENGES AND FUTURE PERSPECTIVES
Henriette, Andre & Wilfred
Presentation for African Region NTP Managers’
meeting 14-16 October 2013, Nairobi, Kenya
11/5/2013 African Region TB Managers' meeting 2013 1
Outline of presentation
1) Basics on Drug Resistant TB
2) Pertinent aspects of Global burden of DR-TB
3) Regional Epidemiological and spatial distribution of DR-TB
4) Progress in control efforts, key issues and challenges, and future perspectives
11/5/2013 African Region TB Managers' meeting 2013 2
Working definition: Bacilli continue to
multiply in the presence of adequate doses of
an otherwise efficacious anti-TB medicine…
1. Mono resistance: resistance to any single anti-TB medicine
2. Poly-resistance: resistance to more than one anti-TB medicine other that Rifampicin and Isoniazid together
3. Multi-Drug Resistance (MDR): resistance to at least Isoniazid and Rifampicin together
4. Extensive drug resistance (XDR-TB): MDR plus Resistance to: 1. A fluoroquinolone : e.g. Ofloxacin, Levofloxacin,
Moxifloxacin 2. At least one second line injectable agents, e.g.
Kanamycin, Amikacin, Capreomycin
11/5/2013 African Region TB Managers' meeting 2013 3
Pathophysiological mechanisms of DR-TB 1) Arising from spontaneous chromosomal mutations at
low frequency. Amplification of the genetic mutation e.g. through human error results in clinically significant drug resistant TB.
2) As a result of man-made selection during treatment: e.g. through erratic drug supply, sub-optimal physician prescription and poor patient adherence…..Molecular mechanisms of drug resistance have been elucidated for the major first- and second-line drugs rifampicin, isoniazid, pyrazinamide, Ethambutol, the aminoglycosides and the fluoroquinolones.
3) Mathematical models predict that the future of an MDR or XDR TB will depend largely on the transmission efficiency or relative fitness of DR-TB compared to drug-susceptible strains (Borrell S, Gagneux S. Int J Tuberculosis and Lung Disease. 2009 Dec;13(12):1456-66.)…to date, this remains unsettled .. studies comparing the spread of DR to drug-susceptible strains suggest that MDR strains can be either 10 times more or 10 times less transmissible
11/5/2013 African Region TB Managers' meeting 2013 4
11/5/2013 African Region TB Managers' meeting 2013 5
Development DR-TB strains (1)
11/5/2013 African Region TB Managers' meeting 2013 6
Development of DR-TB (2)
11/5/2013 African Region TB Managers' meeting 2013 7
11/5/2013 African Region TB Managers' meeting 2013 8
Causes related to Health care providers: leading to inadequate drug regimens
Causes related to anti-TB drugs: e.g. Inadequate supply or poor quality drugs
Causes related to patients: e.g. irregular or inadequate drug intake
Absence of guidelines Poor quality Poor adherence (or poor DOT)
Inappropriate guidelines Unavailability of certain drugs (stock outs or delivery disruptions)
Lack of information
Noncompliance with guidelines
Poor storage conditions Lack of money (no treatment available free of charge, no transport, etc)
Poor training Wrong dose or combination
Adverse drug effects
No monitoring of treatment Social barriers
Poorly organized or funded TB Control Programmes
Malabsorption (e.g. due to concurrent chronic illnesses
Drug Resistant TB is mostly a man-made problem: Common causes of drug resistant Tuberculosis
11/5/2013 African Region TB Managers' meeting 2013 11
Aspects of Global DR-TB burden – M/XDR-TB
11/5/2013 African Region TB Managers' meeting 2013 12
Estimated proportion of TB cases that have MDR-TB by WHO region, 2011. Source: Global TB Report 2012
11/5/2013 African Region TB Managers' meeting 2013 13
Notified cases of MDR-TB as a percentage of MDR-TB cases estimated to occur among notified pulmonary TB cases, 2011
11/5/2013 African Region TB Managers' meeting 2013 14
Countries that had reported at least one case of XDR-TB by end of 2011
11/5/2013 African Region TB Managers' meeting 2013 15
Treatment outcomes for MDR-TB cases by WHO Region, 2009 cohort.
11/5/2013 African Region TB Managers' meeting 2013 16
Regional epidemiological and spatial distribution of DR-TB (M/XDR-TB)
11/5/2013 African Region TB Managers' meeting 2013 17
11/5/2013 African Region TB Managers' meeting 2013
Notified MDR & XDR-TB cases in the African
Region. 2004-2012
18
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
200
4
200
5
200
6
200
7
200
8
200
9
201
0
201
1
201
2
Tot
al
toda
te
MDR-TB 3501 4577 6120 9031 9751 10741 9340 123841812983574
XDR-TB 627 622 486 526 872 1603 3487
3501 4577 6120 9031 9751 10741 9340 12384 18129
83574
Axis
Tit
le
Notified MDR-TB cases East & Southern Africa sub-region
11/5/2013 African Region TB Managers' meeting 2013 19
2004 2005 2006 2007 2008 2009 2010 2011 2012
ESA 3405 4391 6059 8791 9348 10383 8845 11760 17237
AFRO 3501 4577 6120 9031 9751 10741 9340 12384 18129
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000C
ase
s
Notified MDR-TB cases Central Africa sub-region
11/5/2013 African Region TB Managers' meeting 2013 20
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
2004 2005 2006 2007 2008 2009 2010 2011 2012CENTRAL 12 0 1 66 186 124 161 248 315
AFRO 3501 4577 6120 9031 9751 10741 9340 12384 18129
Cas
es
Notified MDR-TB cases West Africa sub-region
11/5/2013 African Region TB Managers' meeting 2013 21
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
2004 2005 2006 2007 2008 2009 2010 2011 2012WEST 84 186 60 174 217 234 334 376 577
AFRO 3501 4577 6120 9031 9751 10741 9340 12384 18129
Cas
es
44 countries have ever reported a case of MDR-TB in the African Region 2004-2012
11/5/2013 African Region TB Managers' meeting 2013 22
Reported MDR cases by year. African Region 2004-2012
Country 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total to date % of notifications
Algeria 0 74 0 0 0 0 56 0 0 130 0.2
Angola 0 0 0 2 0 0 3 40 45 90 0.1
Benin 15 28 21 11 4 14 15 20 25 153 0.2
Botswana 0 12 0 139 126 101 106 46 52 582 0.7
Burkina Faso 0 3 6 31 16 19 31 42 38 186 0.2
Burundi 10 0 0 28 17 0 24 6 24 109 0.1
Cameroon 0 0 0 0 24 26 35 63 153 301 0.4
Cape Verde 0 0 0 5 0 n/r n/r n/r n/r 5 0.0
Central African Republic 0 0 0 0 12 7 9 15 28 71 0.1
Chad 0 0 0 0 0 0 3 0 0 3 0.0
Comoros 0 0 0 0 2 n/r n/r n/r n/r 2 0.0
Congo 0 0 0 21 0 n/r n/r n/r n/r 21 0.0
Côte d'Ivoire 36 47 0 0 24 43 50 30 221 451 0.5
Democratic Republic of the Congo 0 0 1 15 128 91 87 121 65 508 0.6
Equatorial Guinea 2 0 0 0 5 0 0 3 0 10 0.0
Eritrea 0 0 0 0 0 0 0 11 0 11 0.0
Ethiopia 0 0 0 145 130 233 140 212 284 1144 1.4
Gabon nr nr nr nr nr n/r n/r n/r n/r 0 nr Gambia 0 0 1 0 0 n/r n/r n/r n/r 1 0.0
Ghana 2 1 0 7 2 0 4 7 20 43 0.1
Guinea Conakry 1 20 25 36 72 69 31 78 69 401 0.5
Guinea-Bissau 0 0 0 0 0 0 0 2 6 8 0.0
Kenya 36 44 89 82 102 150 112 166 225 1006 1.2
Lesotho 4 0 0 46 0 0 117 64 46 277 0.3
Liberia 0 0 0 0 2 0 0 0 6 8 0.0
Madagascar 10 0 2 5 6 3 3 9 10 48 0.1
Malawi 0 9 0 12 25 6 40 26 27 145 0.2
Mali 8 2 0 11 7 22 12 10 12 84 0.1
Mauritania 0 11 7 14 6 0 35 8 1 82 0.1
Mauritius 0 0 2 0 1 1 2 1 0 7 0.0
Mozambique 75 115 129 163 181 140 165 283 266 1517 1.8
Namibia 0 0 0 291 221 301 214 192 210 1429 1.7
Niger 0 0 0 2 52 24 39 18 35 170 0.2
Nigeria 0 0 0 45 23 28 21 95 107 319 0.4
Rwanda 0 35 0 105 79 78 90 76 58 521 0.6
Sao Tome and Principe 0 0 0 1 0 0 0 4 8 13 0.0
Senegal 20 0 0 10 7 11 38 50 27 163 0.2
Seychelles 0 0 0 0 0 0 0 0 0 0 0.0
Sierra Leone 0 0 0 0 0 0 0 8 0 8 0.0
South Africa 3219 4120 5774 7429 8198 9070 7386 10085 15419 70700 84.6
Swaziland 3 0 0 110 170 190 326 332 280 1411 1.7
Togo 2 0 0 1 2 4 2 4 2 17 0.0
Uganda 17 46 0 67 26 57 93 71 89 466 0.6
United Republic of Tanzania 4 10 13 169 24 24 34 68 42 388 0.5
Zambia 37 0 50 27 56 29 0 0 80 279 0.3
Zimbabwe 0 0 0 1 1 0 17 118 149 286 0.3
Total 3501 4577 6120 9031 9751 10741 9340 12384 18129 83574 100.0
1) Benin
2) Botswana
3) Burkina Faso
4) DRC
5) Ethiopia
6) Kenya
7) Lesotho
8) Mocambique
9) Namibia
10) Nigeria
11) RSA
12) Swaziland
13) Togo
14) Uganda
11/5/2013 African Region TB Managers' meeting 2013 23
14 countries have ever reported at least one case of XDR-TB by September 2013 in African Region
Progress in control efforts & remaining issues and challenges
11/5/2013 African Region TB Managers' meeting 2013 24
Basic DOTS
11/5/2013 African Region TB Managers' meeting 2013 25
Declining but still high burden: Case notification and estimated TB incidence rates by WHO region, 1990-2011. Regional trends in case notification rates (new, relapse cases, all forms) and estimated TB incidence rates (green). Source: Global TB Report 2012
11/5/2013 African Region TB Managers' meeting 2013 26
11/5/2013 African Region TB Managers' meeting 2013
Relatively high unfavorable treatment outcomes:
27
11/5/2013 African Region TB Managers' meeting 2013 28
TB/HIV – Co-infection: High Estimated HIV prevalence in new TB cases 2012 (fuelling TB incidence)
11/5/2013 African Region TB Managers' meeting 2013 29
Percentage of TB patients with known HIV status by Region, 2004-2011: Source: Global TB Report 2012
Status of core TB-HIV indicators and TB deaths African Region 2005-2011 (& 1995-2011)
Known HIV status
% HIV Pos
% on CPT
% on ART
TB deaths new cases
TB deaths Retreated
cases
0
10
20
30
40
50
60
70
80
1995 2000 2005 2009 2010 2011
Namibia: HCT Coverage and HIV prevalence among TB Patients; Namibia 2005-2012
% Tested for HIV
Testing HIV Positive
Positives on ART
Positives on CPT
10
20
30
40
50
60
70
80
90
100
2005 2006 2007 2008 2009 2010 2011 2012
Pe
rce
nta
ge
Year
Ghana: TB-HIV interventions 2006-2012
% HIV pos on CPT
% HIV pos on ART
% tested for HIV
% HIV pos
0.0
20.0
40.0
60.0
80.0
100.0
2006 2007 2008 2009 2010 2011 201211/5/2013 Ghana NTP REview
Malawi: Trend of selected Key TB-HIV indicators
With Known HIV status
Tested HIV Positive
HIV positive on CPT
HIV Positives on ART
0
20
40
60
80
100
120
2005 2008 2009 2010 2011
11/5/2013 African Region TB Managers' meeting 2013 35
0102030405060708090
100
PLHIV TB Screened % TB Pos % IPT
% TB screened for HIV % TB-HIV % CPT
% on ART
Status of core tb / hiv indicators from sentinel surveillance
system. June 2011-july 2012
Zambia: Trends of key indicators
0
10
20
30
40
50
60
70
80
Teasted HIV+ CPT ART
PE
RC
EN
TAG
E
SERVICE
TRENDS OF TB/HIV SERVICES FOR 2007 - 2009
2007
2008
2009
Mozambique: Key Achievements
• Proportion of TB patients tested for HIV has risen from 24% in 2006 to approximately 86% by the end of 2009
• Proportion of HIV positive TB patients started on CPT has risen from 17% in 2006 to 89% by the end of 2009
• The proportion of eligible TB patients accessing ART is declining significantly since 2006 (46% in 2006, 33% in 2007, 30% in 2008 and 22% in 2009),
11/5/2013 African Region TB Managers' meeting 2013 38
Countries in African Region with Xpert MTB-Rif technology as of May 2013. Source: WHO GLI website
Low government funding: Domestic funding as a percentage of total funding available for TB care and control, 2009-2011
11/5/2013
African Region TB Managers' meeting 2013
40
11/5/2013 African Region TB Managers' meeting 2013 41
11/5/2013 African Region TB Managers' meeting 2013
MDR-TB DIAGNOSIS TREATMENT GAP 2009-2011 AFRICAN REGION: ONLY 57% OF DIAGNOSED CASES STARTED ON TREATMENT
42
TB Laboratory services capacity, 2011
11/5/2013 African Region TB Managers' meeting 2013 43
Levels of Diagnostic DST for rifampicin and isoniazid among new TB cases, by Region, 2010
0.2%
5.0%
0.6%
30.4%
0.1% 0.4% 1.8%
0%
5%
10%
15%
20%
25%
30%
35%
AFR AMR EMR EUR SEAR WPR Global
Diagnostic DST for rifampicin and isoniazid Among previously treated TB cases, by Region, 2010
2.8%
18.5%
6.3%
50.7%
0.3% 1.6%
6.4%
0%
10%
20%
30%
40%
50%
60%
AFR AMR EMR EUR SEAR WPR Global
DST coverage for second-line drugs among MDR-TB cases, 2010
0%
10%
20%
30%
40%
50%
60%
70%
AFR AMR EMR EUR SEA WPR Global
The TB Supranational Reference Laboratory (SNRL) Network
11/5/2013 African Region TB Managers' meeting 2013 47
11/5/2013 African Region TB Managers' meeting 2013
Uncertain knowledge of burden: Global coverage of drug resistance surveillance data, 2012
48
Cost issues: Summary of the available evidence on the cost effectiveness of interventions for TB care and control
11/5/2013 African Region TB Managers' meeting 2013 49
Future perspectives
11/5/2013 African Region TB Managers' meeting 2013 50
Basic DOTS enhancement, expansion and quality improvement
11/5/2013 African Region TB Managers' meeting 2013 51
http://www.who.int/tb/publications/2010/2010/en/index.html
The New recommendations in
the new Guidelines
52
Question 1. Should new pulmonary TB patients be
treated with the 6 months or the 2 months
rifampicin regimen?
Recommendations
• New patients should receive a regimen containing 6 months of RIF: 2HRZE / 4HR.
• The treatment regimen with 2 months RIF: 2HRZE/6HE should be phased out.
Supporting evidence
• Regimens with Shorter RIF duration are significantly associated with higher Relapse rates
• Regimens with 2 months of RIF are also somewhat associated with higher Failure rates
• If there is background Isoniazid resistance – the absolute difference between 2 months RIF and 6 months RIF regimens is even greater in terms of unfavorable outcomes
Question 2. Dosing frequency: When a country
selects 2HRZE/4HR, should patients be treated
with a daily or 3 times weekly intensive phase?
Recommendations
• The optimal dosing frequency for new patients with TB is daily throughout the course of therapy (6 months)
• However, New patients may receive a daily intensive phase followed by three times weekly continuation phase
• Three times weekly dosing throughout therapy [2(HRZE)3 / 4(HR)3] is another alternative as long as:
– patient is receiving directly observed therapy of every dose, and
– patient NOT living with HIV or living in a high HIV-prevalent setting.
• New patients with TB should not receive twice weekly dosing for TB treatment for the full treatment
Question 2. Dosing frequency: When a country
selects 2HRZE/4HR, should patients be treated with
a daily or 3 times weekly intensive phase?
• Supporting evidence for the recommendations
i. There is no significant increase in failure, relapse, or acquired
drug resistance in pan-susceptible patients - when comparing
daily dosing throughout therapy with the intermittent regimens
ii. However, Patients receiving three times weekly dosing
throughout therapy had 3.3 times higher rates of acquired
drug resistance than patients who received daily treatment
iii. For patients with background INH resistance, three times
weekly intensive phase was associated with significantly
higher risk of failure and acquired drug resistance
iv. There was insufficient data to support the use of regimens that
are given two times weekly throughout therapy. On operational
grounds, missing one dose means the patient receives only
half the regimen
Question 3. What should be the continuation
phase in countries with high levels of
isoniazid resistance
Recommendations
• In populations with known (or suspected) high
levels of INH resistance, new TB patients may
receive HRE - in the continuation phase ….need
for local representative drug resistance profiles
to first line anti-TB medicines.. DRS data
• Supporting evidence
– Inadequate evidence to quantify the ability of
Ethambutol to “protect rifampicin”
– Expert opinion based
Question 4. Should intermittent regimens be used
for persons living with HIV? What should be the
duration of TB treatment in people living with HIV?
Recommendations
1) TB patients living with HIV and TB patients living in HIV
prevalent settings should receive daily TB treatment (at
least during the intensive phase)
2) For the continuation phase, the optimal dosing frequency
is also daily for these patients
3) If a daily continuation phase is not possible, three times
weekly dosing during the continuation phase is an
acceptable option
4) TB patients living with HIV should receive the same
duration of TB treatment as HIV-negative TB patients
Question 4. Should intermittent regimens be used
for persons living with HIV? What should be the
duration of TB treatment in people living with
HIV?
Supporting evidence
1. Intermittent regimen administered throughout a six
month treatment regimen was associated with at least
double the rate of failure and relapse compared with
daily regimen
2. However, there was no change in failure, relapse and
death rates if the regimen is prolonged to 9 months
3. Use of ARVs significantly reduces failure, relapse and
death rates among these patients … implications
…aim for UA to ARVs for the dually infected /
affected
Question 5. How effective is sputum monitoring
for predicting relapse, failure and pre-treatment
INH resistance?
Recommendations
• For smear positive pulmonary TB patients,
sputum smear microscopy may be performed at
completion of the intensive phase (end 2
months)
• If smear positive at the end of 2 months– repeat
smear microscopy again at the end of 3 months
• If still smear positive at the end of 3 months–
send for culture and DST
Question 5. How effective is sputum monitoring
for predicting relapse, failure and pre-treatment
INH resistance ?
Supporting evidence
1. Sputum smear at the end of 2 or 3 months of
treatment has limited utility in predicting relapse
2. Quality of evidence in most studies that
assessed failure - very low
3. Main rationale for recommending the addition of
a 3 month sputum smear is only to detect poor
response to therapy (due to DR or MDR) earlier
than 5 month
Question 6. In new patients, how effective is
treatment extension for preventing failure or
relapse?
Recommendations
• In patients treated with the regimen containing
Rifampicin for 6 months, if a positive sputum
smear is found at completion of the intensive
phase, the extension of the intensive phase is not
recommended
Question 6.
In new patients, how effective is treatment
extension for preventing failure or relapse?
Supporting evidence
• Preliminary results from 1 moderate quality study
shows only modest benefit in decreasing risk of
relapse
• Historically, when the new patient regimen
included only 2 months of RIF, the extension of the
intensive phase was meant to afford the patient an
extra month of RIF. When the recommended
regimen of 6 month of rifampicin is applied, the
justification for the extra month effectively falls
away
63
Question 7. Treating previously
treated TB cases
• Which (if any) groups of patients should receive
a retreatment regimen with first line drugs?
– What is the best regimen for previously treated
patients, so that if they have MDR, they receive
effective treatment?
The Fall and Rise phenomenon for anti-
TB drug resistance
65
Question 7. Treating previously
treated TB cases
Recommendations
1. All previously treated TB patients should
have culture and DST done before or at the
start of treatment.
2. In settings where rapid DST is available, the
results should guide the choice of regimen
66
Question 7. Previously treated cases
Recommendations 3: In settings where rapid DST results are not routinely
available, empiric treatment should be started as
follows:
i. TB patients returning after defaulting or relapsing from their first line treatment may receive the retreatment regimen containing first line drugs 2HRZES / 1HRZE / 5HRE
ii. TB patients whose treatment has failed or other patient groups with high likelihood of MDR-TB should be started on an empiric MDR regimen.
iii. As soon as DST results known – regimens should be adjusted
iv. NTPs should obtain and use their country-specific drug resistance data of failure, relapse and default patient groups to determine the levels of MDR.
67
Question 7. Previously treated cases
Supporting evidence
• Studies using WHO standard retreatment (2SHRZE/1HRZE/5HRE)
– RCT in Retreatment – None
– RCT in New cases – None
– Cohorts in Retreatment – 12 arms with 1,410
patients
D. Menzies, TDG meeting, Paris 21-23 October 2008
Question 7. Treating previously treated
cases
Supporting evidence • A few Cohort studies have been reported:
– Largest groups were pan-sensitive
– In INH resistant – Varying, but poor results
– In Mixed (most like programme conditions)
• Highly variable results, but mostly POOR
• Perhaps reflecting underlying drug resistance
– No data in Strep resistant, or Poly-drug
resistance (other than MDR)
D. Menzies, TDG meeting, Paris 21-23 October 2008
11/5/2013 African Region TB Managers' meeting 2013 69
Fully implement the 2012 WHO TB/HIV policy
2012 WHO TB/HIV POLICY The 12 points policy package: What's new?
B. Decrease the burden of TB in PLHIV (Three Is for HIV/TB and earlier initiation of ART)
5. Intensify TB case finding and ensure quality TB treatment 6. Introduce TB prevention with IPT and ART 7. Infection control for TB in health care and congregate settings ensured
A. Establish the mechanisms for integrated TB & HIV services 1. Set up and strengthen a TB/HIV coordinating body effective at all levels 2. Conduct HIV and TB surveillance among TB and HIV patients respectively 3. Carry out joint TB/HIV planning 4. Conduct monitoring and evaluation
C. Decrease the burden of HIV in patients with presumptive and diagnosed TB 8. Provide HIV testing & counselling to patients with presumptive and diagnosed TB 9. Introduce HIV preventive methods patients with presumptive and diagnosed TB 10. Provide CPT for TB patients living with HIV 11. Ensure HIV prevention, treatment & care for TB patients living with HIV 12. Provide Antiretroviral therapy to TB patients living with HIV
Section A: Establish mechanisms for integrated TB & HIV services
• Joint TB/HIV coordinating bodies including patients' groups and other line ministries
• HIV surveillance among TB patients including in anti-TB drug resistance surveys; TB surveillance among PLHIV
• Models of integrated delivery of HIV and TB services
• Harmonized indicators and R&R formats; one national M&E system
Section B: Decrease the burden of TB among PLHIV
• TB screening for all PLHIV (adults and children) at every visit using clinical algorithm (four symptoms: cough, fever, los loss of weight and haemoptysis).
• IPT provision or investigations for TB/other diseases • TB diagnosis and treatment by HIV implementers • At least 6 months of IPT; up to 36 months in HIV-
prevalent settings • TST not a requirement for initiating IPT in PLHIV • Earlier initiation of ART for TB prevention in line with
WHO guidelines
Section C: Decrease the burden of HIV in patients with presumptive and
diagnosed TB
• Routine HIV testing for all patients with presumptive and diagnosed TB
• Couple HIV testing and counselling
• Comprehensive HIV prevention methods targeting sexual, parenteral and vertical transmission
• Collaboration with harm reduction, mother and child health and PMTCT services
• ART for all TB patients living with HIV
Intensified TB Case Finding and Isoniazid Preventive Therapy for PLHIV
Summary 2010 Recommendations
TB screening Some Recommendations
Adults and adolescents living with HIV should be
screened with a clinical algorithm of five signs and
Symptoms: 1) current cough, 2) fever, 3) weight loss
4) night sweats or 5) haemoptysis
those who do not report any one of these are unlikely to have active TB and should be offered IPT.
Those with any one of these may have active TB and should
be evaluated for TB and other diseases.
(Strong recommendation, moderate quality evidence)
Inclusion criteria for studies • Collected sputum specimens from PLHIV regardless of
signs or symptoms;
• Used mycobacterial culture of at least one specimen to diagnose TB and;
• Collected data about signs and symptoms.
Top five best performing rules (1 of m) in all subjects (n = 8173)
Combination rule
Sen
(%) Spe (%)
LR-
NPV (95% CI)
5% TB prevalence
CC, F, NS, WL 79 49 0.42 97.7 (97.4-98.0)
H, F, NS, WL 76 53 0.46 97.6 (97.2-98.0)
CC, F, WL 74 54 0.48 97.5 (97.1-97.9)
CC, NS, WL 73 59 0.49 97.5 (97.1-97.8)
CC, F, NS 73 61 0.44 97.7 (97.4-98.0)
CC: cough in the last 24 hours; F: Fever; H: Haemoptysis; NS: Night sweats; WL: Weight loss
Top five best performing rules (1 of m) in all subjects with abnormal CXR (n = 2805)
Combination rule
Sen
(%) Spe (%)
LR-
NPV (95% CI)
5% TB prevalence
CC, F, NS, WL, X 91 39 0.24 98.7 (97.1-99.5)
CC, F, NS, X 89 52 0.21 98.9 (97.6-99.5)
CC, F, WL, X 88 42 0.28 98.5 (96.9-99.3)
H, F, NS, WL, X 87 43 0.29 98.1 (97.3-98.6)
CC, NS, W,L X 87 45 0.29 98.6 (97.5-99.3)
CC: cough in the last 24 hours; F: Fever; H: Haemoptysis; NS: Night sweats; WL: Weight loss
Performance of the best rule (one of current cough, fever, night sweats or weight loss)
Setting
Sen
(%) Spe
(%) LR- (%)
NPV (95% CI)
5% TB prevalence
Community 76 61 0.39 97.3 (96.9-97.7)
Clinical 89 30 0.38 98.3 (97.5-98.8
CD4 < 200 94 22 0.29 98.9 (95.8-99.5)
CD4> 200 83 34 0.49 96.9 (95.1-98.0)
CC: cough in the last 24 hours; F: Fever; H: Hemoptysis; NS: Night sweats; WL: Weight loss
TB screening and IPT algorithm
No Yes
Not TB TB Yes No Other Dx
Screen for TB with any one of the following: Current cough; Fever, Weight loss; Night Sweats
Investigate for TB and other Diseases. Assess IPT contraindications
Person living with HIV
Treat for TB
Appropriate treatment & consider IPT
Defer IPT Give IPT Follow up & consider IPT
Screen for TB regularly, periodically
Role of Xpert MTB/RIF in TB screening among PLHIV
HIV pos HIV neg HIV neg /
unknown
P-Value
Sensitivity in C+
Smear microscopy 44.6%
(86/193)
[37.7% - 51.6%]
68.6%
(234/341)
[63.5% - 73.3%]
72.3%
(613/848)
[69.2% - 75.2%]
<.0001
Xpert MTB/RIF 82.4%
(173/210)
[76.7% - 86.9%]
90.7%
(304/335)
[87.2% - 93.4%]
92.3%
(760/823)
[90.3% - 94.0%]
0.0849
Sensitivity in S+C+
Xpert MTB/RIF
Sensitivity in S-C+
Xpert MTB/RIF
97.7%
(84/86)
[91.9% - 99.4%]
71.8%
(89/124)
[63.3% - 78.9%]
99.0%
(204/206)
[96.5% - 99.7%]
77.5%
(100/129)
[69.6% - 83.9%]
98.4%
(553/562)
[97.0% - 99.2%]
79.3%
(207/261)
[74.0% - 83.8%]
0.2167
0.8976
Specificity in Non-TB
Smear microscopy 100.0%
(660/660)
99.4%
(1054/1060)
99.4%
(3040/3058)
0.2545
Xpert MTB/RIF 99.2%
(389/392)
99.3%
(748/753)
98.9%
(2457/2484)
0.2246
Sensitivity & specificity of Xpert and smear stratified by HIV status
DON’T QUOTE -CONFIDENTIAL
Revised TB/HIV algorithms
Take home message. TB screening among PLHIV
Among PLHIV, Investigate for TB and other diseases by all available means:
Clinical algorithm (key signs and symptoms)
Sputum smear and culture
Chest x-ray
Xpert MTB/RIF
Recommendations on use of Tuberculin Test
Adults and adolescents who are living with
HIV in settings with higher TB transmission and:
have unknown or positive TST status and;
unlikely to have active TB
should receive IPT for at least 36 months
(Conditional recommendation, moderate quality
evidence)
Take home message on TST
• Tuberculin skin test is not a requirement for initiating IPT for people living with HIV
(Strong recommendation)
• Where feasible, TST can be used as people with a positive test benefit more from IPT than those with a negative test
(Strong recommendation)
Take home message on use of IPT
Providing IPT to people living with HIV does not increase the risk of developing INH resistant TB. Therefore concerns regarding the development of INH resistance should not be a barrier to providing IPT.
(Strong recommendation, moderate quality evidence)
TB screening in children
• Children living with HIV who do not have poor weight gain*, fever or current cough are unlikely to have active tuberculosis TB.
(Strong recommendation, low quality evidence)
*Poor weight gain is defined as reported weight loss, or very low weight (weight-for-age less than -3 z-scores), or underweight (weight-for-age less than -2 z-scores), or confirmed weight loss (>5%) since the last visit, or flattening growth curve
Use of IPT in children
1) Children living with HIV who have any one of poor weight gain*, fever, current cough or contact history with a TB case may have TB and should be evaluated for TB and other conditions. If the evaluation shows no TB, children should be offered IPT regardless of their age.
(Strong recommendation, low quality evidence)
2) Children over 12 months of age who are living with HIV and who are unlikely to have active TB on symptom based screening and have no contact with a TB case should receive 6 months of INH preventive therapy (10mg/kg)
(Strong recommendation, moderate quality evidence)
Use of IPT in children (2)
1) Children less than 12 months of age (infants) who:
have contact with an index TB case, and
who have been evaluated for TB (using clinical investigations) and shown no evidence of active TB
Should receive IPT for 6 months
(Conditional recommendation, low quality evidence)
2) All children living with HIV who have successfully
completed treatment for TB disease should receive
INH for an additional 6 months
(Strong recommendation, low quality evidence)
What is new in the guidelines for TB screening and use of IPT among PLHIV
1) Screening for TB only by using symptom based algorithm is sufficient to start IPT for PLHIV
2) CXR and TST are not mandatory requirements for starting IPT
3) Regular screening for active TB at every visit for those on IPT
4) Pregnant women, children, those on ART and those who completed TB treatment should receive IPT
5) Conditional recommendation of 36 months IPT for settings with high TB transmission among PLHIV
Acknowledgements
• Haileyesus and TB/HIV team, WHO Geneva
• Marco Vitoria & HIV Team, WHO Geneva
• TB/HIV Working Group of the STOP TB Partnership
• Members of the Policy Development Group
• Etc., etc.
11/5/2013 African Region TB Managers' meeting 2013 93
Fully implement PMDT GUIDELINES…2008 & 2011
Changes in recommendations on regimen composition
between the 2008 and 2011 updates of the guidelines
Priority questions (1)
1) At what prevalence of MDR-TB in any group of TB patients is rapid drug-susceptibility testing warranted to detect resistance to rifampicin and isoniazid or rifampicin alone on all patients in the group at the time of TB diagnosis, in order to prescribe appropriate treatment at the outset ?
2) Among patients with MDR-TB receiving appropriate treatment in settings with reliable direct microscopy, is monitoring using sputum smear microscopy alone rather than sputum smear and culture, more or less likely to lead to treatment success (and other outcomes) ? 3) When designing regimens for patients with MDR-TB, is the inclusion of specific drugs (with or without documented susceptibility) more or less likely to lead to treatment success (and other outcomes) ?
Priority questions (2)
4) When designing regimens for patients with MDR-TB, is the inclusion of fewer drugs in the regimen (depending on the drug used, the patient’s history of its use and isolate susceptibility) more or less likely to lead to treatment success (and other outcomes) ? 5) In patients with MDR-TB, is shorter treatment, compared with the duration currently recommended by WHO, more or less likely to lead to treatment success (and other outcomes) ? 6) In patients with HIV infection and drug-resistant TB receiving antiretroviral therapy, is the use of drugs with overlapping and potentially additive toxicities, compared with their avoidance, more or less likely to treatment success (and other outcomes) ? 7) Among patients with MDR-TB, is ambulatory therapy, compared with inpatient treatment, more or less likely to lead to treatment success (and other outcomes) ?
Evidence Reviews
Teams based in leading academic centres assessed existent evidence for the questions using :
- Systematic reviews of literature (as per
Cochrane Handbook)
- Meta-analysis of individual patient data
- Simulations using modelling
- Cost-effectiveness analysis
The quality of evidence
Definition Quality
Further research is very unlikely to change our confidence in the estimate of effect.
High
Further research is likely to have an important impact on our confidence in the effect and may change the estimate.
Moderate
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Low
Any estimate of effect is very uncertain. Very low
Guyatt GH et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924-6
Implications of the strength of a
recommendation for different users
Adapted from Guyatt GH et al. GRADE Working Group. Going from evidence to recommendations. BMJ, 2008, 336(7652):1049–1051
Recommendation 1
Rapid drug susceptibility testing (DST) of isoniazid and rifampicin or of rifampicin alone is recommended over conventional testing or no testing at the time of diagnosis of TB, subject to available resources (conditional recommendation / very low quality evidence)
Evidence : simulations from modelling work Rapid DST of INH & RIF at the time of diagnosis was the most cost effective testing strategy for any patient group or setting, even at very low levels of resistance among TB patients (MDR-TB in >1% and isoniazid resistance (other than MDR-TB) in >2%). Rifampicin resistance detected by Xpert MTB/RIF in patient groups in whom MDR is rare has low predictive value and results need to be confirmed by phenotypic DST or line probe assay.
Recommendation 2
The use of sputum smear microscopy and culture rather than sputum smear microscopy alone is recommended for the monitoring of patients with MDR-TB during treatment (conditional recommendation / very low quality evidence)
Evidence : individual patient data and simulations from modelling Monthly sputum smear microscopy and culture was the best strategy in identifying failures earlier. Sputum smear microscopy alone resulted in delayed detection of failure. Sputum smear microscopy results are of use to clinicians in identifying patients likely to fail their treatment and instituting infection control measures in a timely manner. Resource implications are important.
In the treatment of patients with MDR-TB, a fluoroquinolone should be used (strong recommendation / very low quality evidence). In the treatment of patients with MDR-TB, a later-generation fluoroquinolone rather than an earlier-generation fluoroquinolone should be used (conditional recommendation / very low quality evidence). In the treatment of patients with MDR-TB, ethionamide (or prothionamide) should be used (strong recommendation / very low quality evidence).
Recommendations 3 to 5
In the treatment of patients with MDR-TB, four second-line anti-tuberculosis drugs likely to be effective (including a parenteral agent), as well as pyrazinamide, should be included in the intensive phase (conditional recommendation / very low quality evidence). In the treatment of patients with MDR-TB, regimens should include at least pyrazinamide, a fluoroquinolone, a parenteral agent, ethionamide (or prothionamide), and either cycloserine or PAS (p-aminosalicylic acid) if cycloserine cannot be used (conditional recommendation / very low quality evidence).
Recommendations 6 and 7
Groups of second-line drugs
Evidence: meta-analysis of >9000 individual MDR-TB patient data from 32 published observational studies, none being randomised controlled trials (RCTs) Bias may be due to use of certain drugs for sicker patients, incomplete ascertainment of relapse, the under-representation of certain geographical regions, and missing data for some of the variables examined. Adjustments were made to try to counter these limitations but findings from this analysis may not necessarily be generalizeable to all MDR-TB cases. XDR-TB patients were excluded. Clear benefit of fluoroquinolones, particularly later-generation drugs. Among the oral bacteriostatic drugs, the association with cure was higher with ethionamide than with cycloserine, which was higher than with PAS. No particular parenteral agent was considered superior. No effect for Group 5 drugs or ethambutol.
About recommendations 3 to 7
In the treatment of patients with MDR-TB, an intensive phase of at least 8 months’ duration is recommended (conditional recommendation / very low quality evidence). In the treatment of patients with MDR-TB, a total treatment duration of at least 20 months is recommended in patients without any previous MDR-TB treatment (conditional recommendation / very low quality evidence).
Recommendations 8 and 9
About recommendations 8 and 9
Evidence: same individual patient data meta-analysis as was used for treatment regimen composition questions (recommendations 3 to 7) Recommendation is not “pegged” to sputum conversion. Previous recommendations (2008) were to use a parenteral agent for a minimum of 6 months and at least 4 months past culture conversion, and a minimum total length of treatment of 18 months after culture conversion. Most patients may be expected to receive this length of treatment but in some it may have to be modified depending on their bacteriological status and other indicators of treatment progress
Odds of success by duration of treatment
Antiretroviral therapy is recommended for all patients with HIV and drug-resistant TB requiring second-line anti-tuberculosis drugs, irrespective of CD4 cell-count, as early as possible (within the first 8 weeks) following initiation of anti-tuberculosis treatment (strong recommendation / very low quality evidence).
Recommendation 10
Evidence: from 10 observational studies of treatment outcomes when antiretroviral therapy (ART) and second-line anti-tuberculosis drugs were used together. Available data did not allow assessment for a number of outcomes of interest, namely avoiding the additional acquisition of drug resistance, preventing TB transmission, sustaining relapse-free cure, establishing the optimal duration of MDR-TB treatment, avoiding unnecessary MDR-TB treatment, and reducing cost and improving population access to appropriate care. The strength of the recommendation is based in part on indirect evidence from its use in any patient with active TB, which shows large beneficial effects and a very high mortality when ART is not employed, particularly in very immunocompromised patients (CD4 cell-count <50 cells/mm3)
Patients with MDR-TB should be treated using mainly ambulatory care rather than models of care based principally on hospitalization (conditional recommendation / very low quality evidence
Recommendation 11
Evidence : cost-effectiveness modelled for all possible countries using a probabilistic analysis of real data from four countries (Estonia, Peru, Philippines, Russian Fed [Tomsk]). None were from RCTs. The benefit of reduced transmission can only be expected if proper infection control measures are in place in both the home and the clinic. Admission to hospitals for patients who do not warrant it may also have important social and psychological consequences which need to be taken into account. There may be important barriers to accessing clinic-based ambulatory care, including distance to travel and other costs to individual patients. Shifting costs from the service provider to the patient has to be avoided, and implementation may need to be accompanied by appropriate enablers.
Research Gaps
This update revealed important gaps in knowledge, including: - A lack of moderate or high quality evidence from randomized controlled trials for optimizing treatment regimens in patients with MDR-TB, including the best combination of drugs and treatment duration; - Lack of evidence for optimal drug regimens for treating patients with isoniazid resistance, with XDR-TB and with non-MDR-TB polydrug-resistance; - Very limited information about treatment of paediatric MDR-TB; - Identification of the most effective chemoprophylaxis for contacts of MDR-TB cases; - The therapy for symptomatic relief from adverse reactions linked to second-line anti-tuberculosis drugs.
Acknowledgements
WHO/HQ Léopold Blanc, Chris Duncombe, Dennis Falzon, Christopher Fitzpatrick, Katherine Floyd, Haileyesus Getahun Malgorzata Grzemska, Christian Gunneberg, Ernesto Jaramillo, Christian Lienhardt, Fuad Mirzayev, Paul Nunn, Mario C. Raviglione, Delphine Sculier, Marco Antonio de Avila Vitoria, Fraser Wares, Karin Weyer, Matteo Zignol Guideline Development Group Jaime Bayona, José A. Caminero, Charles L. Daley, Agnes Gebhard, Myriam Henkens, Timothy H. Holtz, Joël Keravec, Salmaan Keshavjee, Aamir J. Khan, Vaira Leimane, Andrey Mariandyshev, Carole D. Mitnick, Gloria Nwagboniwe, Domingo Palmero, Ma. Imelda Quelapio, Michael L. Rich, Sarah Royce, Sabine Rüsch-Gerdes, Archil Salakaia, Rohit Sarin, Holger Schünemann, Elena Skachkova, Francis Varaine External Review Group Samiha Baghdadi, Mercedes Becerra, Vineet Bhatia, Masoud Dara, Mirtha del Granado, Reuben Granich, Lindiwe Mvusi, Nani Nair, Norbert Ndjeka, Wilfred A.C Nkhoma, Katsunori Osuga, Hendrik Simon Schaaf, Catharina van Weezenbeek, Irina Vasilyeva, Wang Xie Xiu, Richard Zaleskis Evidence review teams Harvard University, US - Chunling Lu, Carole D. Mitnick, Richard A. White McGill University, Canada - Melissa Bauer, Richard (Dick) Menzies, Olivia Oxlade University of California (San Francisco), US - Gail Kennedy, George Rutherford, Karen Steingart University of Washington, US - Matthew Arentz, David Horne, Patricia Pavlinac, Judd L. Walson Consultant Patricia Whyte
Companion manual
Later into (perhaps in 2014), it is planned to have a manual to assist in the implementation of the principles contained in the Guidelines
(an update of the document hereunder).
Recommended models of care for DR-TB…WHO NOW RECOMMENDS AMBULATORY MODELS
…including community based care
• Hospital-based?
• Out-patient?
• Community-based?
• Mixed models ?
11/5/2013 African Region TB Managers' meeting 2013 114
Hospitalization vs. outpatient care for the intensive phase of treatment
• Hospitalization
– Easier to do in some health systems
– DOT easier
– Facilitates training on clinical management
but requires:
– infection control
– guaranteed funding and bed capacity
– ethical issues addressed
• Out-patient care
– Socially acceptable
– Lower cost
– DOT more challenging
but requires:
– Access to a primary health care network
– Strong social support
– Community-based care in many cases
– Infection control
11/5/2013 African Region TB Managers' meeting 2013 115
Some core aspects to consider in choosing model of care
1) Effectiveness (treatment outcomes)
2) Cost-effectiveness
3) Sustainability
Which model can handle the estimated country MDR-TB burden until the epidemic dwindles?
11/5/2013 African Region TB Managers' meeting 2013 116
Factors influencing low adherence to treatment
• personal factors • poor understanding of the disease and treatment requirements, adverse
side effects to drugs),
• socioeconomic factors (i.e., stigma, poverty, lack of family and community support)
• health system factors • inadequate staffing and attitude
• poor patient-provider relations,
• inconvenient treatment arrangements,
• and erratic or insecure drug supply
• patients from marginalized groups • prisoners,
• homeless,
• drug and alcohol users
• migrants
11/5/2013 African Region TB Managers' meeting 2013 117
What do patients need ?
- Psychological support (depression, affirming life in face of death, voice fears)
- Social support (involve family and community)
- Involving patient in treatment decision (willing to stop TB treatment?)
- Management of symptoms (breathlessness, pain, etc)
- Nutritional support
- Spiritual counselling whenever is requested/ demanded
11/5/2013 African Region TB Managers' meeting 2013 118
Examples of patients support interventions in GLC regions
Region Food Transport
Vouchers
Hygiene
Packets
Counseling
Support
Housing
Support
Education Financial
Incentive
s
Skills-building
Workshops
AFRO 12/22 6/22 0/22 9/22 2/22 1/22 1/22 2/22
AMRO 4/16 2/16 0/16 8/16 0/16 1/16 2/16 1/16
EMRO 4/8 2/8 0/8 4/8 0/8 1/8 3/8 0/8
EURO 43/52 26/52 18/52 32/52 2/52 9/52 7/52 1/52
SEARO 4/9 3/9 0/9 4/9 2/9 0/9 1/9 1/9
WPRO 5/10 4/10 0/10 4/10 1/10 1/10 0/10 0/10
Totals 72/117 43/117 18/117 61/117 8/117 13/117 14/117 5/117
11/5/2013 African Region TB Managers' meeting 2013 119
Common current flow for MDR-TB management
DR-TB Patients are diagnosed at health facilities
Referred to MDR-TB hospitals for initiation of treatment and initial hospitalization
Patients admitted and started on standard regimen
(
Patients kept for approx. 6 months or till 2 negative cultures
Then referred back to the health facility to continue treatment
Follow-up done at MDR-TB hospitals on monthly basis
11/5/2013 120
Issues associated with centralised care
Nearly half of diagnosed cases are not started on treatment
1-2 months of waiting for admission, sometimes more Long distance of transportation for admission and follow
up Negative impact on social and economic status of the
individual and family due to a long stay in hospital Risk of transmission in hospital due to inadequate
implementation of infection control measures Non-uniformity in current, sporadic efforts of
decentralized management Issues of refusal to admission and aggressive demand for
early discharge Poor outcome of DR-TB cases
11/5/2013 121
Solutions
11/5/2013 122
Solutions Advantages Challenges
Increase no. of hospitals/ beds
• Convenient to the health system
• Cost to the government/ patients • Socio-economic problems • Risk of transmission if inadequate IC • Sustainability
Decentralized management of DR-TB cases including community DOT
• Early initiation of treatment
Reduce morbidity/ mortality Reduce transmission
• Convenient for the patients •Cost effective • Improve adherence • More sustainable
• Establishment of new infrastructure • Increase training need • Other sector s/ Community involvement • Increase demand for supervision
Possible decentralized management of MDR-TB:
Principles
1. Ned for clarity of functions across all levels
2. Need for linkages to existing TB services and to the entire health system
11/5/2013 123
Requirements for the decentralized MDR-TB care
Prompt and accurate MDR-TB diagnosis
Trained multidisciplinary team with adequate and effective mentorship and supervision
Guidelines/protocols for clinical management
Uninterrupted supply of second line anti-TB drugs
Adequate infrastructure and infection control measures
Integration with local TB programme activities as well as HIV and PHC;
11/5/2013 124
Requirement for the decentralized MDR-TB care
Criteria for selection of patients to receive treatment in the community and defaulter tracing mechanism
Communication between the different levels of the health care system, including effective Advocacy, Communication and Social Mobilization.
Rigorous monitoring and evaluation: indicators to be defined
Ring fenced resources dedicated to providing specialized MDR-TB staff
11/5/2013 125
Central MDR/X-DR TB Unit /
Hospital
Decentralised (?
District) MDR-TB Unit
Satellite MDR-TB Unit
Satellite MDR-TB Unit
Mobile MDR-TB
Unit/Injection team
PHC Clinic PHC Clinic
Mobile MDR-TB
Unit/Injection team
Community DOTS Plus supporters/Households
Sample model of decentralized MDR-TB CARE
Sample proposed patient flow (1) Diagnosis at Health Care Facility
Refer to the nearest Centralized/ Decentralized DR-TB Unit
Initiation of treatment and
Hospitalization if indicated Managed on ambulatory
(smear pos, very sick, XDR, (all smear neg, stable)
side-effects)
11/5/2013 127
Sample proposed patient flow (2) Hospitalized cases
Discharged after
(smear conversion/ stable for MDR; culture conversion for XDR)
Referred to nearest health facility to continue treatment
(health facility will be prepared for DR-TB management)
Monitored on regular basis by Centralized/ Decentralized units
11/5/2013 128
Sample proposed patient flow (3) Ambulatory cases
Managed at all category of DR-TB units/ health facility/ community supporters/ mobile teams
Monitored by closest Centralized/ Decentralized units
(responsible for registering and reporting)
11/5/2013 129
DR-TB and Human Rights
1) Limitation and derogation clauses in the international
human rights instruments recognize that States at certain
times may need to limit rights. Such clauses are primarily
intended to protect the rights of individuals when States
perceive that such limitations must take place.
2) Restrictions must be in accordance with the law, in the
interest of legitimate aims, and strictly necessary for the
promotion of general welfare in a democratic society.
3) Where several types of limitations are available, the least
restrictive alternative must be adopted.
4) Even where, on grounds of protecting public health, such
limitations are basically permitted— based on a set of
principles called the Siracuse Principles—they should be of
limited duration and subject to review
11/5/2013 African Region TB Managers' meeting 2013 130
The 5 Siracuse Principles 1. The restriction is provided for and carried out in
accordance with the law;
2. The restriction is in the interest of a legitimate objective of general interest;
3. The restriction is strictly necessary in a democratic society to achieve the objective;
4. There are no less intrusive and restrictive means available to reach the same goal; and
5. The restriction is not imposed arbitrarily, i.e. in an unreasonable or otherwise discriminatory manner.
11/5/2013 African Region TB Managers' meeting 2013 131
Strategic action area 1 :Preventing the generation of drug-resistant TB forms – actions to close the tap
Strategic action area 2: Establishing the magnitude of DR-TB
Strategic action area 3: Promoting and supporting development and scale up of programmatic management of drug-resistant TB
Strategic action area 4: Developing / strengthening National and Regional DR-TB surveillance systems
Strategic action area 5: Addressing Health system challenges: Increased access to TB services through decentralisation, infrastructure development, initiatives to remove financial barriers to access (UHC concept), enhanced laboratory quality and networks, etc.; increased and sustained TB control financing: Health workforce capacity building; working with all providers & strategic Health information
Strategic action area 6: Operations Research 11/5/2013 African Region TB Managers' meeting 2013 132
Core strategic actions for country and regional response to DR-TB
Information on “Short course treatment regimens” for MDR-TB (1)
• Current official WHO’s guidelines for MDR-TB recommend 8 months intensive phase and a total duration of 20 months in most patients [Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. (WHO/HTM/TB/2011.6). Geneva, World Health Organization, 2011 & Ahuja SD et al. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Med. 2012, 9(8):e1001300].
• In the past few years one observational study from Bangladesh using shorter regimens (9-12 months) yielded much higher treatment success than is usually achieved with the longer regimens [Van Deun A et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182(5): 684–692]. Some AFRO countries (Benin, Burundi, Cameroon, CAR and Cote D’Ivoire) have applied to conduct OR on this with WHO support.
11/5/2013 African Region TB Managers' meeting 2013 133
Current WHO Position on short course regimens for MDR-TB
Until sufficient evidence is available to inform a change in policy, WHO is advising countries on a case-by-case basis to introduce short MDR-TB regimens under the following conditions: ■Treatment is delivered under operational research conditions following international standards (including Good Clinical Practice and safety monitoring), with the objective of assessing the effectiveness and safety of these regimens; ■The project is approved by a national ethics review committee with proper attention to regulatory and ethical issues, ahead of any patient enrolment; and ■The programmatic management of DR-TB and the corresponding research project are monitored by an independent monitoring board set up by, and reporting to WHO.
11/5/2013 African Region TB Managers' meeting 2013 134
11/5/2013 African Region TB Managers' meeting 2013
Source: Prof Diane Havlir. Maputo TB/HIV Meeting, April 2013
135
11/5/2013 African Region TB Managers' meeting 2013 136
Core Recommendations on use of BEDAQUILINE
11/5/2013 African Region TB Managers' meeting 2013 137
WHO INTERIM POLICY RECOMMENDATIONS ON USE OF BEDAQUILINE
11/5/2013 African Region TB Managers' meeting 2013 138
BEDAQUILINE USE RECOMMENDATIONS
11/5/2013 African Region TB Managers' meeting 2013 139
BEDAQUILINE USE RECOMMENDATIONS
11/5/2013 African Region TB Managers' meeting 2013 140
DRUG RESISTANT TB DIAGNOSTIC PATHWAYS
11/5/2013 African Region TB Managers' meeting 2013 141
ENHANCING COUNTRY CAPACITY TO DIAGNOSE TB: Smear, C & DST, and Molecular technologies including WHO endorsed Xpert & LPA
Countries eligible for FIND negotiated prices on Xpert MTB/RIF equipment
1. Algeria
2. Angola
3. Benin
4. Botswana
5. Burkina Faso
6. Burundi 7. Cape Verde
8. Cameroon
9. Central African Republic
10. Chad
11. Comoros
12. Congo( Brazzaville) 13. DR Congo
14. Eritrea
15. Ethiopia
16. Gabon
17. Gambia
18. Ghana
19. Guinea
20. Guinea Bissau
21. Ivory Coast 22. Kenya
23. Liberia
24. Madagascar
25. Malawi 26. Mali 27. Mauritania
28. Mozambique
29. Namibia
30. Niger
31. Nigeria
32. Rwanda
33. Senegal 34. Seychelles
35. Sierra Leone
36. South Africa
37. Tanzania
38. Togo
39. Uganda
40. Zambia
41. Zimbabwe 11/5/2013 African Region TB Managers' meeting 2013 143
Key Recommendations for
ART in Adults and
Adolescents
WHO 2013 ARV Guidelines Launch
Dr. Meg Doherty
Summary of Changes in Recommendations When to Start in Adults
TARGET POPULATION (ARV-NAIVE)
2010 ART GUIDELINES 2013 ART GUIDELINES
STRENGTH OF RECOMMENDATION
& QUALITY OF EVIDENCE
HIV+ ASYMPTOMATIC CD4 ≤350 cells/mm3
CD4 ≤500 cells/mm3 (CD4 ≤ 350 cells/mm3 as a priority)
Strong, moderate-quality evidence
HIV+ SYMPTOMATIC
WHO clinical stage 3 or 4 regardless of CD4 cell count
No change Strong, moderate-quality evidence
PREGNANT AND BREASTFEEDING WOMEN WITH HIV
CD4 ≤350 cells/mm3 or WHO clinical stage 3 or 4
Regardless of CD4 cell count or WHO clinical stage
Strong, moderate-quality evidence
HIV/TB CO-INFECTION
Presence of active TB disease, regardless of CD4 cell count
No change Strong, low-quality evidence
HIV/HBV CO-INFECTION
Evidence of chronic active HBV disease, regardless of CD4 cell count
Evidence of severe chronic HBV liver disease, regardless of CD4 cell count
Strong, low-quality evidence
HIV+ PARTNERS IN SD COUPLE
No recommendation established
Regardless of CD4 cell count or WHO clinical stage
Strong, high-quality evidence
Recommendations: CD4 Independent Conditions
INITIATE ART REGARDLESS OF CD4 COUNT OR CLINICAL STAGE
RECOMMENDATION
ADULTS WITH HIV…
…and active TB disease Strong, low-quality evidence
…and HBV co-infection with severe liver disease
Strong, low-quality evidence
…who are pregnant or breastfeeding Strong, moderate-quality of evidence
…in a HIV serodiscordant partnership
Strong, high-quality evidence
CHILDREN < 5 YEARS OLD WITH HIV
Infants diagnosed in the first year of life
Strong, moderate-quality of evidence
Children infected with HIV between one and below five years of age
Conditional, very-low-quality evidence
FIRST-LINE REGIMENS (PREFERRED ARV REGIMENS)
TARGET
POPULATION 2010 ART GUIDELINES 2013 ART GUIDELINES
STRENGTH &
QUALITY OF
EVIDENCE
HIV+ ADULTS AZT or TDF + 3TC (or
FTC) + EFV or NVP
TDF + 3TC (or FTC) + EFV
(as fixed dose
combination)
Strong,
moderate-quality
evidence
HIV+ PREGNANT
WOMEN AZT + 3TC + NVP or EFV
HIV/TB
CO-INFECTION
AZT or TDF + 3TC (or
FTC) + EFV
HIV/HBV
CO-INFECTION
TDF + 3TC (or FTC) +
EFV
Summary of Changes in Recommendations:
What to Start in Adults
1st Line ART
Adults and Adolescents (including pregnant women, TB co-infection and
HBV co-infection)
Preferred
Regimens
TDF+3TC (or FTC) + EFV
Alternative
Regimens
AZT+ 3TC + EFV (or NVP)
TDF+ 3TC (or FTC)+ NVP
Special situations
ABC +3TC+EFV (or NVP)
AZT (or ABC)+ 3TC
+ LPV/r or ATV/r
One regimen cannot fit all: preferred, alternative, special situations
Rationale: One Regimen For All
• Simplicity: regimen is very effective, well tolerated and available as a single, once-daily FDC and therefore easy to prescribe and easy to take for patients – facilitates adherence
• Harmonizes regimens across range of populations (Adults, Pregnant Women (1st trimester), Children >3 years, TB and Hepatitis B)
• Simplifies drug procurement and supply chain by reducing number of preferred regimens (phasing out d4T)
• Safety in pregnancy
• Efficacy against HBV
• EFV is preferred NNRTI for people with HIV and TB (pharmacological compatibility with TB drugs) and HIV and HBV coinfection (less risk of hepatic toxicity)
• Affordability (cost declined significantly since 2010)
Preferred 1st line regimen: TDF + 3TC (or FTC) + EFV
Managing Co-infections
TB in the 2013 Consolidated Guidelines • Synthesis of existing recommendations
http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf
http://whqlibdoc.who.int/publications/2009/9789241598323_eng.pdf
http://whqlibdoc.who.int/publications/2012/9789241503006_eng.pdf
Co-trimoxazole Recommendations (2006) Planned revision early 2014
AGE CRITERIA FOR INITIATION Contraindications: severe sulfa allergy, severe liver or renal disease and G6PD deficiency
HIV-EXPOSED INFANTS
Universal, starting at 4–6 weeks after birth
<1 YEAR Universal 1
1–5 YEARS WHO clinical stages 2, 3 and 4 regardless of CD4 % OR Any WHO stage and CD4 <25% OR Universal 1
≥5 YEARS, INCLUDING ADULTS
Any WHO stage and CD4 count <350 cells/mm3 2 OR WHO 3 or 4 irrespective of CD4 level OR Universal 1
1 Universal regardless of CD4 percentage or clinical stage in settings with high HIV prevalence, high infant mortality due to infectious diseases and limited health infrastructure. 2 Some countries may choose to adopt a CD4 threshold of <200 cells/mm3. 3 In settings with high prevalence of bacterial infections or malaria.
CRITERIA FOR DISCONTINUATION (Stevens-Johnson syndrome, severe liver disease, anaemia, pancytopaenia or HIV -ve status)
Until risk of HIV transmission ends HIV excluded
Until 5 years of age regardless of CD4% or clinical symptoms OR Never
Never
Never or when CD4 ≥350 cells/mm3 after 6 months of ART 3
OR CD4 ≥200 cells/mm3 after 6 months of ART
TB Screening Algorithm in Adults
Adults and adolescents living with HIV should be screened for TB with a clinical algorithm; those who report any one of the symptoms of current cough, fever, weight loss or night sweats may have active TB and should be evaluated for TB and other diseases (strong recommendation, moderate-quality evidence).
TB patients with known positive HIV status and TB patients living in HIV-prevalent settings should receive at least six months of rifampicin treatment regimen (strong recommendation, high-quality evidence).
TB Screening in Children
Children living with HIV who have any of the following symptoms of poor weight gain, fever or current cough or contact history with a TB case may have TB and should be evaluated for TB and other conditions. If the evaluation shows no TB, children should be offered isoniazid preventive therapy regardless of their age (strong recommendation, low quality evidence).
Isoniazid Preventive Therapy (IPT)
IPT reduces the incidence of TB in PLHIV even if they are on ART
Offer IPT to all PLHIV who do not have TB even if they are on ART Adult and adolescents and children living with HIV should be screened with a clinical algorithm; those who do not report any one of the symptoms of current cough, fever, weight loss or night sweats are unlikely to have active TB and should be offered IPT (strong recommendation, moderate-quality evidence). Children and adults living with HIV who are contacts of TB patients should be screened and evaluated for TB. Those without TB should be offered IPT (strong recommendation, very low quality of evidence)
Diagnosis of TB in PLHIV
Xpert MTB/RIF should be used as the initial diagnostic test in persons with HIV and suspected MDR-TB
(strong recommendation)
• Sputum smear microscopy has a very low
TB detection rate among PLHIV compared with sputum culture and Xpert MTB/Rif
Xpert MTB/RIF • Fully automated molecular test • Suitable for use outside laboratory • simultaneously detects TB disease and
rifampicin resistance within 2 hours • Detects 92% of culture-positive TB
http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf
TB Treatment and ART in PLHIV
• ART should be started in all TB patients living with HIV irrespective of their CD4 counts
(strong recommendation, low quality of evidence)
• Start TB treatment first using a rifampicin containing regimen
• Start ART asap within the first 8 weeks of TB treatment
(strong recommendation, moderate quality of evidence)
• Patients with CD4< 50 cells/mm3 should receive ART immediately with the first 2 weeks of initiating TB treatment
ART in PLHIV and TB Adults, adolescents and children over 3 years
Efavirenz is preferred NNRTI in patients starting ART (TDF + 3TC (or FTC) + EFV ) while on TB treatment
(strong recommendation, high-quality evidence)
Rifampicin reduces effective concentrations of PIs
If rifabutin available use standard PI regimens
If rifabutin not available provide double dose Lopinavir/ritonavir(LPV/r) (800mg/200mg or 400mg/400mg twice daily)
Preferred first-line ART regimen
Second-line ART regimen
Children and Infants Initiating TB Treatment while Receiving ART
If on a standard NNRTI-based regimen (two NRTIs + EFV or NVP)
continue NVP (ensure dose is 200 mg/m2) OR Triple NRTI (AZT + 3TC + ABC)
If on standard PI-based regimen (two NRTIs + LPV/r)
Triple NRTI (AZT + 3TC + ABC) OR Substitute NVP for LPV/r (ensure dose is 200 mg/m2) OR Continue LPV/r (consider adding RTV to achieve the full therapeutic dose)
Interactions between rifampicin and LPV/r or NVP mean that TBHIV co-treatment in children under three years needs ART modification
Once TB therapy has been completed, this regimen should be stopped and the original regimen should be restarted (strong recommendation, moderate-quality evidence)
SUMMARY : Pertinent DR-TB control issues in the Region & barriers to scale up
1) High burden of TB & TB/HIV co-infection
2) Very high preventable unfavorable programme performance indicators
3) Sub-optimal political & programmatic strategic policy environment for PMDT leading to significant diagnosis / treatment gap
4) Inadequate laboratory diagnostic capacity and networks for DR-TB diagnosis and follow up
5) Limited availability of SLDs
6) Health system challenges: access to health services; Infrastructure; HRH; funding; surveillance systems; etc, etc
11/5/2013 African Region TB Managers' meeting 2013 161
Thank you for your attention
Comments
Clarifications Questions
11/5/2013 African Region TB Managers' meeting 2013 162